MaxCyte fundraising was oversubscribed



Panmure Gordon acted as nominated adviser, joint broker and joint bookrunner for MaxCyte’s successful £25.1 million fundraising. The funds will be used to accelerate and strengthen the company’s global leadership in non-viral cell engineering by building balance sheet strength as it looks ahead to a Nasdaq IPO.

The offering was led by Casdin Capital, a US life science-focused investment firm, and Sofinnova Partners, a European life sciences investment firm.

Freddy Crossley, Panmure Gordon’s Head of Healthcare, said: “We are delighted to continue to support MaxCyte’s development plans and were pleased to have two specialist healthcare funds join the high quality list of existing shareholders, in this challenging market.”

The transaction follows the successful private placement last week for Faron Pharmaceuticals, which raised EUR14 million and for which Panmure Gordon was sole UK bookrunner and corporate broker.  Panmure Gordon also acted as sole broker and nominated adviser for Inland Homes’ successful £10 million fundraising.

Other insights like this

View all